scholarly journals LSP1 Gene rs3817198 Polymorphism and Breast Cancer Risk: A Systematic Review and Meta-analysis Study

2016 ◽  
Vol 1 (4) ◽  
pp. 77-82
Author(s):  
Ali Sanjari Moghaddam ◽  
Morteza Roodgar ◽  
Hamid Mansourpour ◽  
Alireza Mosavi Jarrahi
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Genetic Model ◽  
Association Studies ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Random Effect ◽  
Small Study ◽  
Genome Wide Association Studies

In this meta-analysis, we tried to clear the relationship between breast cancer risk and LSP1 gene rs3817198T>C polymorphism. This meta-analysis was conducted according to PRISMA protocol. We searched PubMed/Medline, Web of sciences and EMBASE. All literature investigating the association of LSP1 gene rs3817198T>C and breast cancer risk were considered to include in the meta-analysis. We pooled ORs using both fixed and random-effect models. Egger’s test and funnel plot were used to evaluate Publication bias and small study effect. After evaluation and screening of citations, 14 publications were eligible for final analysis after applying of inclusion and exclusion criteria. Overall, 30,204 cases and 35,282 controls included in this meta-analysis. There was the significant association between LSP1 gene rs3817198T>C polymorphism and breast cancer only in homozygote genetic model (OR=1.14 [1.05-1.24]) and no association was found in heterozygotes (OR=1.03 [0.98-1.07]). The association was significant for popula ion-based studies and European & American & African population in both homozygote and heterozygote genetic model. There was no evidence of bias of literature and no small study effect. In conclusion, it seems that LSP1 gene rs3817198 polymorphism play its role in breast cancer incidence and other SNPs and environment are such triggers. Nevertheless, we recommend genome-wide association studies to evaluate the effect of SNPs in combination, not as single SNPs.

scholarly journals Identifying 31 novel breast cancer susceptibility loci using data from genome-wide association studies conducted in Asian and European women

2019 ◽  
Author(s):  
Xiang Shu ◽  
Jirong Long ◽  
Qiuyin Cai ◽  
Sun-Seog Kweon ◽  
Ji-Yeob Choi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Association Studies ◽  
Meta Analysis ◽  
Genome Wide Association Studies ◽  
Asian Populations ◽  
Risk Variants ◽  
Genome Wide ◽  
European Women

ABSTRACTCommon genetic variants in 183 loci have been identified in relation to breast cancer risk in genome-wide association studies (GWAS). These risk variants combined explain only a relatively small proportion of breast cancer heritability, particularly in Asian populations. To search for additional genetic susceptibility loci for breast cancer, we performed a meta-analysis of data from GWAS conducted in Asians (24,206 cases and 24,775 controls). Variants showing an association with breast cancer risk at P < 0.01 were evaluated in GWAS conducted in European women including 122,977 cases and 105,974 controls. In the combined analysis of data from both Asian and European women, the lead variant in 28 loci not previously reported showed an association with breast cancer risk at P < 5 ×10−8. In the meta-analysis of all GWAS data from Asian and European descendants, we identified SNPs in three additional loci in association with breast cancer risk at P < 5 ×10−8. The associations for 10 of these loci were replicated in an independent sample of 16,787 cases and 16,680 controls of Asian women (P < 0.05). Expression quantitative trait locus (eQTL) and gene-based analyses provided evidence for the possible involvement of the YBEY, MAN2C1, SNUPN, TBX1, SEMA4A, STC1, MUTYH, LOXL2, and LINC00886 genes underlying the associations observed in eight of these 28 newly identified risk loci. In addition, we replicated the association for 78 of the 166 previously reported risk variants at P < 0.05 in women of Asian descent using GWAS data. These findings improve our understanding of breast cancer genetics and etiology and extend to Asian populations previous findings from studies of European women.

scholarly journals Dominant and Recessive Genetic Models of LSP1 Gene rs3817198 Polymorphism and Breast Cancer Risk: A Systematic Review and Meta-analysis Study

2018 ◽  
Vol 3 (1) ◽  
pp. 5-9
Author(s):  
Ali Sanjari Moghaddam ◽  
Morteza Roodgar ◽  
Hamid Mansourpour ◽  
Alireza Mosavi Jarrahi
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Publication Bias ◽  
Genetic Model ◽  
Meta Analysis ◽  
Random Effect ◽  
Genetic Models ◽  
Funnel Plot ◽  
Dominant Genetic Model

Objective: The aim of this meta-analysis was to discover the effect of dominant and recessive genetic models of LSP1 gene rs3817198 polymorphism on breast cancer risk. Material and Method: We performed this meta-analysis according to PRISMA protocol. Three databases, including PubMed/Medline, Web of sciences, and EMBASE were searched. In this meta-analysis, we included all studies that evaluated the association between LSP1 gene rs3817198 and breast cancer risk. ORs and their reported 95% confidence interval (CI) for dominant and recessive inheritance models were extracted from final retrieved studies. ORs were pooled using both fixed and the random-effect models. Egger’s test and contour-enhanced funnel plot were used to evaluate publication bias and small study effect. Twelve publications were eligible for final analysis after observing our defined inclusion and exclusion criteria. Results: Totally, this meta-analysis composed of 15,530 cases and 20,258 controls. This study revealed a significant association between LSP1 gene rs3817198 polymorphism and breast cancer in the dominant genetic model (OR=1.07 [1.01-1.14]). Inversely, no association was found in the recessive genetic model (OR=1.10 [0.93-1.32]). Subgroup analysis displayed a significant association in population-based studies and European & American and African population only in the dominant genetic model. Begg’s funnel plot and Egger’s test revealed no publication bias. Conclusion: According to our findings, it seems that LSP1 gene rs3817198 polymorphism is associated with breast cancer risk and this risk is more prominent in Caucasians.

scholarly journals Sleep duration and breast cancer incidence: results from the Million Women Study and meta-analysis of published prospective studies

SLEEP ◽  
2020 ◽  
Author(s):  
Angel T Y Wong ◽  
Alicia K Heath ◽  
Tammy Y N Tong ◽  
Gillian K Reeves ◽  
Sarah Floud ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Sleep Duration ◽  
Cancer Incidence ◽  
Prospective Studies ◽  
Average Duration ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Weighted Average

Abstract Study Objectives To investigate the association between sleep duration and breast cancer incidence, we examined the association in a large UK prospective study and conducted a meta-analysis of prospective studies. Methods In the Million Women Study, usual sleep duration over a 24-h period was collected in 2001 for 713,150 participants without prior cancer, heart problems, stroke, or diabetes (mean age = 60 years). Follow-up for breast cancer was by record linkage to national cancer registry data for 14.3 years on average from the 3-year resurvey. Cox regression models yielded multivariable-adjusted breast cancer relative risks (RR) and 95% confidence intervals (CIs) for sleep duration categories. Published prospective studies of sleep duration and breast cancer risk were included in a meta-analysis, which estimated the inverse-variance weighted average of study-specific log RRs for short and for long versus average duration sleep. Results After excluding the first 5 years to minimize reverse causation bias in the Million Women Study, 24,476 women developed breast cancer. Compared with 7–8 h of sleep, the RRs for &lt;6, 6, 9, and &gt;9 h of sleep were 1.01 (95% CI, 0.95–1.07), 0.99 (0.96–1.03), 1.01 (0.96–1.06), and 1.03 (0.95–1.12), respectively. In a meta-analysis of 14 prospective studies plus the Million Women Study, including 65,410 breast cancer cases, neither short (RR &lt; 7 h = 0.99 [0.98–1.01]) nor long (RR &gt; 8 h = 1.01 [0.98–1.04]) versus average duration sleep was associated with breast cancer risk. Conclusions The totality of the prospective evidence does not support an association between sleep duration and breast cancer risk.

Linoleic acid and breast cancer risk: a meta-analysis

2015 ◽  
Vol 19 (8) ◽  
pp. 1457-1463 ◽  
Author(s):  
Yunping Zhou ◽  
Tao Wang ◽  
Shenyong Zhai ◽  
Wei Li ◽  
Qiang Meng
Keyword(s):  
Breast Cancer ◽  
Linoleic Acid ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Random Effect ◽  
Case Control Studies ◽  
Acid Intake ◽  
Linoleic Acid Intake ◽  
Study Heterogeneity

AbstractObjectivePrior studies on linoleic acid, the predominant n-6 fatty acid, and breast cancer risk have generated inconsistent results. We performed a meta-analysis to summarize the evidence regarding the relationship of dietary and serum linoleic acid with breast cancer risk.DesignPertinent studies were identified by a search of PubMed and EMBASE. The fixed- or random-effect pooled measure was selected based on between-study heterogeneity.ResultsEight prospective cohort studies and four prospective nested case–control studies, involving 10 410 breast cancer events from 358 955 adult females across different countries, were included in present study. Compared with the lowest level of linoleic acid, the pooled relative risk (RR; 95 % CI) of breast cancer was 0·98 (0·93, 1·04) for the highest level of linoleic acid. The pooled RR (95 % CI) for dietary and serum linoleic acid were 0·99 (0·92, 1·06) and 0·98 (0·88, 1·08), respectively. The RR (95 % CI) of breast cancer was 0·97 (0·91, 1·04), 0·95 (0·85, 1·07), 0·96 (0·86, 1·07), 0·98 (0·87, 1·10) and 0·99 (0·85, 1·14) for linoleic acid intake of 5, 10, 15, 20 and 25 g/d, respectively. The risk of breast cancer decreased by 1 % (RR=0·99; 95 % CI 0·93, 1·05) for every 10 g/d increment in linoleic acid intake.ConclusionsThis meta-analysis indicated that both dietary linoleic acid intake and serum linoleic acid level were associated with decreased risk of breast cancer, although none of the associations were statistically significant. Further investigations are warranted.

Metformin and breast cancer risk: A meta-analysis and critical literature review.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 25-25
Author(s):  
Nananda Col ◽  
Leslie Ochs ◽  
Vicky Springmann ◽  
Aaron K Aragaki ◽  
Rowan T. Chlebowski
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Literature Review ◽  
Cancer Incidence ◽  
Invasive Breast Cancer ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Cochrane Library ◽  
Study Quality

25 Background: Observational studies have suggested that metformin, commonly used for diabetes treatment that increases insulin sensitivity and improves glycemic control, decreases the incidence of several common cancers. However, findings regarding metformin and breast cancer incidence have been mixed. To explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. Methods: We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching Pub Med, Cochrane Library, Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms". When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR using and performed sensitivity analyses on duration of metformin use (> or < 3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). Results: From a total of 421 citations, 13 full-text articles were considered, and 7 independent studies were included. All were observational (4 cohort and 3 case control). Our combined OR for metformin association with invasive breast cancer of all 7 studies was 0.83 (95% CI, 0.71-0.97). Funnel plot analyses did not suggest publication bias. Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin duration (OR = 0.75. 95% CI, 0.62-0.91) or among studies that began observing their cohort before 1997 (OR=0.68. 95% CI, 0.55-0.84). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Conclusions: Our analyses support a protective effect of metformin on invasive breast cancer incidence among postmenopausal women with diabetes. Clinical trials are needed to determine whether metformin reduces breast cancer risk.

FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma

Blood ◽  
2012 ◽  
Vol 119 (4) ◽  
pp. 1029-1031 ◽  
Author(s):  
Yussanne P. Ma ◽  
Flora E. van Leeuwen ◽  
Rosie Cooke ◽  
Annegien Broeks ◽  
Victor Enciso-Mora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Hodgkin Lymphoma ◽  
Association Studies ◽  
Genome Wide Association Studies ◽  
Nucleotide Polymorphisms ◽  
Control Series ◽  
Cancer Risk Factors ◽  
Increased Risk

Abstract Women treated at young ages with supradiaphragmatic radiotherapy for Hodgkin lymphoma (HL) have a highly increased risk of breast cancer. For personalized advice and follow-up regimens for patients, information is needed on how the radiotherapy-related risk is affected by other breast cancer risk factors. Genome-wide association studies have identified 14 independently replicated common single nucleotide polymorphisms that influence breast cancer risk. To examine whether these variants contribute to risk of radiation-associated breast cancer in HL, we analyzed 2 independent case-control series, from the United Kingdom and The Netherlands, totaling 693 HL patients, 232 with breast cancer and 461 without. rs1219648, which annotates the FGFR2 gene, was associated with risk in both series (combined per-allele odds ratio = 1.59, 95% confidence interval: 1.26-2.02; P = .000111). These data provide evidence that genetic variation in FGFR2 influences radiation-induced breast cancer risk.

scholarly journals Breast Cancer Risk in Rheumatoid Arthritis: An Update Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Guo Tian ◽  
Jia-Ning Liang ◽  
Zhuo-Yun Wang ◽  
Dian Zhou
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Cochrane Library ◽  
Number Of Patients ◽  
The Impact

Background. The incidence of breast cancer in RA patients remains controversial. Thus we performed a meta-analysis to investigate the impact of RA on breast cancer.Methods. Published literature was available from PubMed, Embase, and Cochrane Library. Pooled standardized incidence rate (SIR) was computed by random-effect model analysis.Results. We identified 16 separate studies in the present study, in which the number of patients ranged from 458 to 84,475. We did not find the increased cancer risk in RA patients (SIR=0.86, 95%CI=0.72–1.02). However, subgroup analysis showed that breast cancer risk in RA patients was positively different in Caucasians (SIR=0.82, 95%CI=0.73–0.93) and non-Caucasians (SIR=1.21, 95%CI=1.19–1.23), respectively. In subgroup analysis by style, a reduced incidence was found in hospital-based case subjects (SIR=0.82, 95%CI=0.69–0.97). Similarly, subgroup analysis for adjusted factors indicated that in A3 (age and sex) and A4 (age, sex, and race/ethnicity) the risk was decreased (SIR=0.87, 95%CI=0.76–0.99;SIR=0.63, 95%CI=0.59–0.67).Conclusions. The meta-analysis revealed no increased breast cancer risk in RA patients. However, in the subgroup analysis, the risk of breast cancer is increased in non-Caucasians patients with RA while it decreased in Caucasian population, hospital-based case subjects, and A3 group. Such relationship may provide preference for risk of breast cancer in different population.

scholarly journals Family History of Breast Cancer and Breast Cancer Risk Between Malays Ethnicity in Malaysia and Indonesia: A Meta-Analysis

2019 ◽  
Author(s):  
Ricvan Dana NINDREA ◽  
Teguh ARYANDONO ◽  
Lutfan LAZUARDI ◽  
Iwan DWIPRAHASTO
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Random Effect ◽  
Cancer Type ◽  
History Of ◽  
Published Research ◽  
Random Effect Models

Background: Breast cancer is the most common cancer type in women not only in world but also in Malays ethnicity between Malaysia and Indonesia. Breast cancer has varying incidence in every country, but genetic factor by family history influence the incidence of breast cancer. This systematic review and meta-analysis was performed to determine family history of breast cancer and breast cancer risk between Malays ethnicity in Malaysia and Indonesia. Methods: This meta-analysis was conducted on published research articles on family history of breast cancer and breast cancer risk between Malays ethnicity in Malaysia and Indonesia published between Jan 1999 and Jul 2018 in the online article databases of PubMed, ProQuest and EBSCO. Pooled odds ratios (OR) were calculated with fixed and random-effect models. Publication bias was visually evaluated by using funnel plots and statistically assessed through Egger’s and Begg’s tests. Data were processed using Review Manager 5.3 (RevMan 5.3) and Stata version 14.2 (Stata Corporation). Conclusion: This analysis confirmed the association of family history of breast cancer and breast cancer risk between Malays ethnicity in Malaysia and Indonesia.

Sign in / Sign up

Export Citation Format

Share Document